Real World & Late Phase Research (RWLPR), Quintiles

First published: 20/03/2015

Last updated: 20/08/2024





Institution identification

PURI
https://redirect.ema.europa.eu/resource/8998
Institution ID
8998
Institution countries France
Type of institution Other
Institution website https://www.quintiles.com
ENCePP partner

Institution description

No

Determining the right approach to achieve research objectives requires expertise and experience in real-world and late phase research. Quintiles, a leader in interventional IIIb/IV studies and observational research, is the world's largest provider of biopharmaceutical development and commercial outsourcing services. Whether monitoring safety and evaluating benefit risk or demonstrating effectiveness and gaining market access or proving efficacy in new indications and new formulations, Quintiles offers you a comprehensive approach to evidence development. Patient registries – Experience in conducting product, disease and pregnancy registries. Quality of life and patient-reported outcomes – Evidence to support benefits/claims in product labeling. Safety outcomes/REMS – Safety and risk monitoring over longer periods of time, also monitoring off-label use. Comparative effectiveness – Studies to provide evidence of effectiveness in different populations. Health outcomes/health economics –

Institution details

Experience with collecting data directly from individual patients or respondents:

Yes

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

Contact

Pierre ENGEL



pierre.engel@quintiles.com